<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 3
TO
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
ALEXION PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.0001 PAR VALUE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
015351109
------------
(CUSIP Number)
Mark H. Swartz
Executive Vice President
c/o Tyco International (US) Inc.
One Tyco Park
Exeter, NH 03833
(603) 778-9700
Michael W. Lyons
Corporate Counsel
United States Surgical Corporation
150 Glover Avenue
Norwalk, Connecticut 06856
(203) 845-1000
with a copy to:
Frederick W. Kanner, Esq.
Dewey Ballantine LLP
1301 Avenue of the Americas
New York, New York 10019-6092
(212) 259-8000
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
DECEMBER 30, 1998
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box / /.
NOTE: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.
(Continued on following pages)
(Page 1 of 7 Pages)
<PAGE>
SCHEDULE 13D
<TABLE>
<CAPTION>
- ------------------------------------- --------------------------------------------
CUSIP NO. 015351109 PAGE 2 OF 7 PAGES
--------------------------- ------- -------
- ------------------------------------- --------------------------------------------
- ---------------------------------------------------------------------------------------------
<S> <C> <C>
1
NAME OF REPORTING PERSON: Tyco International Ltd.
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:
Not Applicable
- ---------------------------------------------------------------------------------------------
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/
(b) / /
- ---------------------------------------------------------------------------------------------
3
SEC USE ONLY
- ---------------------------------------------------------------------------------------------
4
SOURCE OF FUNDS*
Not Applicable
- ---------------------------------------------------------------------------------------------
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e) / /
- ---------------------------------------------------------------------------------------------
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
- ---------------------------------------------------------------------------------------------
7
SOLE VOTING POWER
NUMBER OF SHARES
BENEFICIALLY Not Applicable
OWNED BY
EACH
REPORTING
PERSON
WITH
------------------------------------------------------------------------
8
SHARED VOTING POWER
Not Applicable
------------------------------------------------------------------------
9
SOLE DISPOSITIVE POWER
Not Applicable
------------------------------------------------------------------------
10
SHARED DISPOSITIVE POWER
Not Applicable
- ---------------------------------------------------------------------------------------------
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- ---------------------------------------------------------------------------------------------
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
Not Applicable
- ---------------------------------------------------------------------------------------------
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
- ---------------------------------------------------------------------------------------------
14
TYPE OF REPORTING PERSON*
CO
- ---------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
<PAGE>
SCHEDULE 13D
<TABLE>
<CAPTION>
- ------------------------------------ ----------------------------------
CUSIP NO. 015351109 PAGE 3 OF 7
----------------------- ------- ------- PAGES
- ------------------------------------ ----------------------------------
- -------------------------------------------------------------------------------------------
<S> <C> <C>
1
NAME OF REPORTING PERSON: United States Surgical Corporation
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON:
132518270
- -------------------------------------------------------------------------------------------
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) /X/
(b) / /
- -------------------------------------------------------------------------------------------
3
SEC USE ONLY
- -------------------------------------------------------------------------------------------
4
SOURCE OF FUNDS*
Not Applicable
- -------------------------------------------------------------------------------------------
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d)
or 2(e) / /
- -------------------------------------------------------------------------------------------
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------------------
7
SOLE VOTING POWER
NUMBER OF
SHARES Not Applicable
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
--------------------------------------------------------------------------
8
SHARED VOTING POWER
Not Applicable
--------------------------------------------------------------------------
9
SOLE DISPOSITIVE POWER
Not Applicable
--------------------------------------------------------------------------
10
SHARED DISPOSITIVE POWER
Not Applicable
- -------------------------------------------------------------------------------------------
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
- -------------------------------------------------------------------------------------------
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* / /
Not Applicable
- -------------------------------------------------------------------------------------------
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
0%
- -------------------------------------------------------------------------------------------
14
TYPE OF REPORTING PERSON*
CO
- -------------------------------------------------------------------------------------------
</TABLE>
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION
<PAGE>
Tyco International Ltd., a Bermuda company ("Tyco") and United
States Surgical Corporation, a Delaware corporation and an indirect wholly owned
subsidiary of Tyco ("US Surgical") hereby further amend and supplement Statement
on 13D previously filed by Tyco and US Surgical (the "Schedule 13D") relating to
the common stock $.0001 par value (the "Common Stock"), of Alexion
Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"), originally filed
with the Securities and Exchange Commission (the "Commission") on February 29,
1996, as amended. The item numbers and responses thereto below are in accordance
with the requirements of Schedule 13D.
Unless otherwise indicated herein, each capitalized term used but
not defined herein shall have the meaning assigned to such term in the
Schedule 13D. The term Reporting Persons means Tyco and US Surgical.
The Schedule 13D is hereby amended as follows:
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
(a) Number of Shares Beneficially Owned:
As of the date hereof, the Reporting Persons own an aggregate
of 0 shares of Common Stock of the Issuer.
(b) Sole Power to Vote, Direct the Vote of, Dispose of, or Direct
the Disposition of Shares:
Not Applicable.
(c) Recent Transactions:
On December 30, 1998, the Reporting Persons sold 824,087
shares of Common Stock of the Issuer in open market
transactions at a price of $11.625 per share.
(d) Rights with Respect to Dividends on Sales Proceeds:
Not Applicable.
(e) Date of Cessation of Five Percent Beneficial Ownership:
12/30/98.
(Page 4 of 7 Pages)
<PAGE>
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
Item 7 of the Schedule 13D is hereby amended and supplemented by the
following:
<TABLE>
<CAPTION>
EXHIBIT NO. DESCRIPTION
- ----------- -----------
<S> <C>
1 Agreement of Joint Filing pursuant to Rule 13d-1(k)(1)
promulgated under the Securities Exchange Act of 1934,
as amended.
</TABLE>
(Page 5 of 7 Pages)
<PAGE>
After reasonable inquiry and to the best knowledge and belief of the
undersigned, the undersigned certifies that the information set forth in this
statement is true, complete and correct.
Date: January 21, 1999
TYCO INTERNATIONAL LTD.
By: /s/ MARK H. SWARTZ
-----------------------------------------
Name: Mark H. Swartz
Title:Executive Vice President, Chief
Financial Officer
UNITED STATES SURGICAL CORPORATION
By: /s/ MARK H. SWARTZ
-----------------------------------------
Name: Mark H. Swartz
Title: Vice President
(Page 6 of 7 Pages)
<PAGE>
Exhibit 1
Agreement of Joint Filing
Pursuant to 13d-1(k)(1) promulgated under the Securities Exchange
Act of 1934, as amended, the undersigned persons hereby agree to file with the
Securities and Exchange Commission the Statement on Schedule 13D (the
"Statement") to which this Agreement is attached as an exhibit, and agree that
such Statement, as so filed, is filed on behalf of each of them.
IN WITNESS WHEREOF, the undersigned have executed this Agreement.
TYCO INTERNATIONAL LTD.
By: /s/ MARK H. SWARTZ
-----------------------------------------
Name: Mark H. Swartz
Title: Executive Vice President, Chief
Financial Officer
UNITED STATES SURGICAL CORPORATION
By: /s/ MARK H. SWARTZ
-----------------------------------------
Name: Mark H. Swartz
Title: Vice President
(Page 7 of 7 Pages)
